<?xml version="1.0" encoding="UTF-8"?>
<p>As mimic of the main proton shuttling residue (i.e. histidine), histamine (
 <xref ref-type="fig" rid="F0001">Figure 1</xref>) is the main lead for designing CAAs
 <xref rid="CIT0008" ref-type="bibr">
  <sup>8</sup>
 </xref>. The binding mode of histamine with hCA II was elucidated by X-ray crystallography (
 <xref ref-type="fig" rid="F0002">Figure 2</xref>)
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>. In the CAA/enzyme adduct, a complex network of H-bonds involve the Zn-bound water molecule, His64 and the imidazole ring of the activator, located far away from the metal ion (
 <xref ref-type="fig" rid="F0002">Figure 2</xref>). Successive X-ray crystallographic studies showed that many other amines and amino acids (
 <xref ref-type="fig" rid="F0001">Figure 1</xref>) bind in this area and share flexible tails decorated with protonable moieties (
 <xref ref-type="fig" rid="F0002">Figure 2</xref>)
 <xref rid="CIT0038" ref-type="bibr">
  <sup>38–40</sup>
 </xref>. No isoform-selective CAAs were detected so far among these amines and amino acid derivatives, except for few exceptions (e.g. histamine shows a 10 nM K
 <sub>A</sub>s against hCAs VA and XIV but is a micromolar activator of the remaining isoforms)
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>. The molecule of histamine has been extensively modified (
 <xref ref-type="fig" rid="F0003">Figure 3</xref>), including substituents on the imidazole C atoms (
 <bold>A</bold>)
 <xref rid="CIT0041" ref-type="bibr">
  <sup>41</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0042" ref-type="bibr">
  <sup>42</sup>
 </xref>, replacing the imidazole ring with other heterocycles, such as 2,4,6-trisubstituted pyridinium (
 <bold>B</bold>), 1,3,4-thiadiazole (
 <bold>C</bold>) or a combination of these two ring systems (
 <bold>D</bold>)
 <xref rid="CIT0043" ref-type="bibr">
  <sup>43</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0044" ref-type="bibr">
  <sup>44</sup>
 </xref> and functionalising the NH
 <sub>2</sub> group, as in carboxamides/ureas/thioureas (
 <bold>E</bold>)
 <xref rid="CIT0045" ref-type="bibr">
  <sup>45</sup>
 </xref>, sulphonamides (
 <bold>F</bold>)
 <xref rid="CIT0046" ref-type="bibr">
  <sup>46</sup>
 </xref>, arylsulfonylureas (
 <bold>G</bold>)
 <xref rid="CIT0047" ref-type="bibr">
  <sup>47</sup>
 </xref>, bis-histamine (
 <bold>H</bold>)
 <xref rid="CIT0048" ref-type="bibr">
  <sup>48</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0049" ref-type="bibr">
  <sup>49</sup>
 </xref>, oligopeptides
 <xref rid="CIT0049" ref-type="bibr">
  <sup>49</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0050" ref-type="bibr">
  <sup>50</sup>
 </xref>, or imidazole/imidazoline derivatives of the alkaloyd spinaceamine
 <xref rid="CIT0051" ref-type="bibr">
  <sup>51</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0052" ref-type="bibr">
  <sup>52</sup>
 </xref> and drug clonidine
 <xref rid="CIT0053" ref-type="bibr">
  <sup>53</sup>
 </xref> (
 <xref ref-type="fig" rid="F0003">Figure 3</xref>) were reported to possess improved CA activatory profile when potency and isoform selectivity are concerned.
</p>
